ARCHIVES

Over Half of ALK-Positive NSCLC Patients Responded To Crizotinib In Colorado Study

This article is from The Cancer Letter archive.

Vol. 33 No. 11 | November 26, 2010

Download PDF Visit The Full Archive

Related Articles

House Committee Hits “Earmarks” For diseases; Broder Is Lectured On Occupational Exposures

May 21, 1993

NCI spends A Third Of Its Budget On Prevention

May 15, 1992

DCT Board Approves Major Clinical Trials Changes, Regional Groups, New Effort In Surgical Oncology

October 10, 1980

ACS Funds Pilot Study Of Mammography Trial

July 28, 1995

CPRIT Sets Funding Priorities For Rare and Pediatric Cancers

November 14, 2014

Chemical Society Designates Taxol, Camptothecin Discoveries Historic

April 25, 2003